translated from Spanish: Sputnik V: two million doses of the vaccine arrive in the country at the weekend

On the last hours the president, Alberto Fernández, had announced from Yapeyú, Corrientes and as part of the event in commemoration of the 243rd anniversary of the birth of José de San Martín, he had announced that in the coming days more vaccines against the coronavirus would arrive in Argentina. Finally in the last hours it was finished to know that in the coming hours two planes of Aerolíneas Argentinas will depart for the city of Moscow to look for two million doses of the total compromised. 

From the first arrival that took place in December 2020, the present is the shipment with the highest amount of dose since the agreement was signed between the national government and the Russian Direct Investment Fund.It is estimated that the first of the flights will depart from 16:00 and close to that time will do the same the second plane , waiting for the return of them for the closing of the sunday day. Vaccine production
On this day it was also known that the Richmond laboratory in Argentina signed a memorandum of understanding with the Management Society of the Russian Direct Investment Fund, to produce the Sputnik V vaccine against coronavirus in the country. The development of the Russian vaccine in Argentina will involve Hetero Labs Limited, a laboratory in the Republic of India with which Richmond has had a strategic alliance for more than 25 years. The agreement was signed in Moscow by Tagir Sitdekov, representing the RDIF, and Marcelo Figueiras, president of Richmond, according to a note from the local company published in the media. It is worth remembering that Argentina was one of the first countries to begin receiving the headings of the Russian-born Sputnik V vaccine developed by the Gamaleya Institute.The Richmond laboratory has a production plant in the Municipality of Pilar and recently launched an $80 million investment plan planned for the next five years. On February 2nd, the medical journal The Lancet published data on Phase III of the Sputnik V vaccine. According to the analysis published by the prestigious British journal – and validated by independent experts – the Russian vaccine proved 91.6% effective and no serious adverse effects were found.
In this note:

Original source in Spanish